ArticleInternational journal of molecular sciences2024
Cytotoxic Activity of Curcumin- and Resveratrol-Loaded Core-Shell Systems in Resistant and Sensitive Human Ovarian Cancer Cells.
Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resveratrol Nanoformulations for Cancer Management: A Comprehensive Review of Disease-Specific Strategies and Clinical Translational Barriers.International journal of nanomedicine · 2026Review
- Curcumin's Therapeutic Potential in Ovarian Cancer: Current Insights and Future Perspectives.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Due to the high mortality rate of ovarian cancer, there is a need to find novel strategies to improve current treatment modalities. Natural compounds offer great potential in this field but also require the careful design of systems for their delivery to cancer cells. Our study explored the anticancer effects of novel resveratrol (RSV)- and curcumin (CUR)-loaded core-shell nanoparticles in human ovarian cancer cells. We evaluated the in vitro cytotoxicity of various nanocarriers (CUR 1-3, RSV I-III) delivered to MDAH-2774 and SKOV-3 cells in comparison to free RVS and CUR after 24 h and 72 h treatment. A two-way ANOVA was applied to compare the results of the MTT assay. Confocal laser scanning microscopy was employed to visualize cellular uptake and mitochondrial localization. Our findings revealed that the cytotoxicity of the core-shell nanoparticles with RSV was not significant, but the systems loaded with CUR effectively decreased the viability of cells. The MDAH-2774 cell line was more sensitive to the treatment than SKOV-3. The enhanced cellular uptake of CUR delivered by core-shell systems and its colocalization with mitochondria were demonstrated. Further research focused on the detailed biological effects of the most effective systems (CUR 2 and CUR 3) should be conducted to provide detailed insights. These findings highlight the promising role of CUR-loaded nanoparticles in ovarian cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.